ICD-10 Coding for Chemotherapy-Induced Anemia(D63.0, D63.0U, D64.81)
Learn about the ICD-10 coding for chemotherapy-induced anemia, including documentation requirements, coding pitfalls, and billing considerations.
Complete code families applicable to Chemotherapy-Induced Anemia
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D64.81 | Anemia due to antineoplastic chemotherapy | Use when anemia is directly linked to chemotherapy treatment. |
|
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs | Use alongside D64.81 to indicate adverse effects of chemotherapy. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutChemotherapy-Induced Anemia
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Chemotherapy-Induced Anemia.
Omitting the adverse effect code
Impact
Clinical: Incomplete clinical picture of treatment effects., Regulatory: Non-compliance with coding standards., Financial: Potential loss of reimbursement for adverse effects.
Mitigation
Always include T45.1X5A with D64.81., Review documentation for adverse effects.
Incorrect sequencing of codes
Impact
Reimbursement: May affect DRG assignment and reimbursement levels., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Ensure D64.81 is listed first when anemia is the primary focus of care.
Documentation of causality
Impact
Failure to document the link between anemia and chemotherapy.
Mitigation
Implement documentation templates that require causality statements.